The correlation between fibroblast growth factor-23 and ESRD patients with hearing impairment

BACKGROUND: End-stage renal disease (ESRD) patients often experience hearing impairment, resulting in a high rate of disability and a decline in their quality of life. Fibroblast growth factor-23 (FGF23) is a diagnostic biomarker for chronic kidney disease (CKD) and a pathogenic contributor to CKD p...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Jingwen, Li, Qing, Guo, Min, Li, Jiaqing, Yang, Jiahui, Chang, Qing, Cai, Yaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520394/
https://www.ncbi.nlm.nih.gov/pubmed/34721981
http://dx.doi.org/10.7717/peerj.12295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520394/
https://www.ncbi.nlm.nih.gov/pubmed/34721981
http://dx.doi.org/10.7717/peerj.12295

Ejemplares similares